金凯生科股东青松投资持有公司股份4,801,374股(占公司总股本比例3.99%)。青松投资计划通过集中竞 价方式减持公司股份不超过1,204,000股，减持比例不超过公司总股本的1%。集中竞价的减持期间为自 本减持计划公告之日起十五个交易日后的三个月内。 中国经济网北京6月5日讯金凯生科（301509）(301509.SZ)昨晚披露的关于公司股东减持股份的预披露 公告显示，公司于近日分别收到股东启鹭(厦门)股权投资合伙企业(有限合伙)(以下简称"启鹭投资")、青 岛青松创业投资集团有限公司-青岛松凯创业投资企业(有限合伙)(以下简称"青松投资")提交的《关于减 持金凯(辽宁)生命科技股份有限公司股份计划的告知函》。 金凯生科股东启鹭投资持有公司股份7,140,500股(占公司总股本比例5.93%)。启鹭投资计划通过集中竞 价和大宗交易方式减持公司股份不超过3,612,000股(占公司总股本比例3%)。其中，通过集中竞价方式减 持股份不超过1,204,000股，减持比例不超过公司总股本的1%；通过大宗交易方式减持股份不超过 2,408,000股，减持比例不超过公司总股本的2%。集中竞价或大宗交易的减持期间为自 ...

Core Viewpoint - The A-share medical service sector experienced a short-term decline, with significant drops in several companies' stock prices, indicating potential market volatility in this industry [1] Company Summary - Jinkai Biotechnology saw a decline of over 8% in its stock price [1] - Other companies that followed the downward trend include Sunshine Nuohuo, Tigermed, Hongbo Pharmaceutical, Berry Genomics, and Chengdu Xian Dao [1]

Group 1 - The healthcare sector has experienced a short-term decline, with Jinkai Biotechnology (301509) dropping over 8% [1] - Other companies such as Hongbo Pharmaceutical (301230), Baicheng Pharmaceutical (301096), Chengdu XianDao, and Wanbang Pharmaceutical (301520) also saw declines [1] - There is a notable influx of dark pool capital into these stocks, indicating potential interest from institutional investors [1]

Core Viewpoint - Shareholders Qilu Investment and Qingsong Investment plan to collectively reduce their holdings by no more than 4% of the company's shares [1] Summary by Relevant Categories Shareholder Actions - Qilu Investment intends to reduce its stake by up to 3%, with a maximum of 1% through centralized bidding and 2% via block trading [1] - Qingsong Investment plans to reduce its stake by up to 1% through centralized bidding [1] Timeline - The reduction period will be within three months starting from fifteen trading days after the announcement date [1]

Group 1 - The core point of the announcement is that shareholders Qi Lu Investment and Qingsong Investment plan to reduce their holdings in Jinkai Biotechnology (301509) by a total of up to 361.2 million shares, which represents 3% of the company's total share capital [1] - Qi Lu Investment intends to reduce its stake by up to 120.4 million shares through centralized bidding, accounting for 1% of the total share capital, and by up to 240.8 million shares through block trading, accounting for 2% of the total share capital [1] - Qingsong Investment plans to reduce its stake by up to 120.4 million shares through centralized bidding, also representing 1% of the total share capital [1] Group 2 - The reduction period for these share sales will be within three months starting from fifteen trading days after the announcement date [1]

金凯（辽宁）生命科技股份有限公司 关于公司股东减持股份的预披露公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、青岛青松创业投资集团 有限公司－青岛松凯创业投资企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）股东启鹭（厦门）股权 投资合伙企业（有限合伙）（以下简称"启鹭投资"）持有公司股份7,140,500股（占 公司总股本比例5.93%）。启鹭投资计划通过集中竞价和大宗交易方式减持公司股份不 超过3,612,000股（占公司总股本比例3%）。其中，通过集中竞价方式减持股份不超过 1,204,000股，减持比例不超过公司总股本的1%；通过大宗交易方式减持股份不超过 2,408,000股，减持比例不超过公司总股本的2%。集中竞价或大宗交易的减持期间为自 本减持计划公告之日起十五个交易日后的三个月内。 公司股东青岛青松创业投资集团有限公司－青岛松凯创业投资企业（有限合伙） （以下简称"青松投资"）持有公司股份4,801,374股（ ...

Market Overview - As of June 3, the Shanghai Composite Index closed at 3361.98 points, up 14.49 points, with a gain of 0.43% [1] - The Shenzhen Component Index closed at 10057.17 points, up 16.54 points, with a gain of 0.16% [1] - The ChiNext Index closed at 2002.70 points, up 9.51 points, with a gain of 0.48% [1] High Turnover Stocks - A total of 78 A-shares had a turnover rate exceeding 20% on June 3 [1] - Notable stocks with high turnover rates include: - Xiongdi Technology (300546) with a turnover rate of 61.20% and a closing price of 25.18 yuan, up 0.72% [1] - New World (301277) with a turnover rate of 51.25% and a closing price of 17.55 yuan, up 11.01% [1] - Kangliyuan (301287) with a turnover rate of 43.10% and a closing price of 37.70 yuan, up 12.98% [1] Additional High Turnover Stocks - Other stocks with significant turnover rates include: - C Guqi (001390) at 42.61% turnover, closing at 25.65 yuan, down 5.07% [1] - Guangkang Biochemical (300804) at 42.51% turnover, closing at 44.68 yuan, up 5.75% [1] - Wangzi New Materials (002735) at 42.39% turnover, closing at 17.70 yuan, down 10.02% [1] Summary of Turnover Rates - The data indicates a trend of increased trading activity in certain stocks, with several companies experiencing significant fluctuations in their share prices alongside high turnover rates [1][2][3]

证券代码：301509 证券简称：金凯生科 公告编号：2025-017 金凯（辽宁）生命科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"或"发行人"） 2024年年度权益分派方案已获2025年5月19日召开的2024年度股东会审议通过，现 将权益分派事宜公告如下： 一、股东会审议通过的利润分配方案情况 1、公司2024年度利润分配方案为：以截至2024年12月31日公司总股本 120,446,669股为基数，向全体股东每10股派发现金红利人民币4.00元（含税）， 合计派发现金红利人民币48,178,667.60元（含税）；不送红股；资本公积金不转 增股本；剩余未分配利润结转至以后年度。本次利润分配完成后，本年度累计现 金分红总额48,178,667.60元，占公司本年度合并报表归属于母公司所有者净利润 的124.79%。 率征收，本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股期限计算 应纳税额【注】；持有首发后限售股、股权激励限售股及无限售流通股的证券 ...

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].

证券代码：301509 证券简称：金凯生科 公告编号：2025-016 金凯（辽宁）生命科技股份有限公司 2024 年度股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2025 年 5 月 19 日（星期一）下午 14：00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 5 月 19 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00— 15:00；通过深圳证券交易所互联网系统投票的具体时间为 2025 年 5 月 19 日 9:15—15:00。 2、召开地点：辽宁省阜新市阜蒙县伊吗图镇氟化工园区安仁路 6 号金凯（辽 宁）生命科技股份有限公司会议室。 5、主持人：董事长 FUMIN WANG（王富民）先生。 6、本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东 会规则》《深圳证券交易所创业板股票上市规则 ...